The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Abstract
Alzheimer's disease (AD) is characterized by a chronic and progressive neurodegenerative process resulting from the intracellular and extracellular accumulation of fibrillary proteins: beta‐amyloid and hyperphosphorylated Tau. Overaccumulation of these aggregates leads to synaptic dysfunction and subsequent neuronal loss. The precise molecular mechanisms of AD are still not fully understood but it is clear that AD is a multifactorial disorder and that advanced age is the main risk factor. Over the last decade, more than 50 drug candidates have successfully passed phase II clinical trials, but none has passed phase III. Here, we summarize data on current “anti‐Alzheimer's” agents currently in clinical trials based on findings available in the Thomson Reuters «Integrity» database, on the public website www.clinicaltrials.gov, and on database of the website Alzforum.org. As a result, it was possible to outline some major trends in AD drug discovery: (i) the development of compounds acting on the main stages of the pathogenesis of the disease (the so‐called “disease‐modifying agents”) — these drugs could potentially slow the development of structural and functional abnormalities in the central nervous system providing sustainable improvements of cognitive functions, which persist even after drug withdrawal; (ii) focused design of multitargeted drugs acting on multiple molecular targets involved in the pathogenesis of the disease; (3) finally, the repositioning of old drugs for new (anti‐Alzheimer's) application offers a very attractive approach to facilitate the completion of clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E., & Klug, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.4051 · Cited by 1,134
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Role of oxidative stress in Alzheimer’s disease
HUANG, W.-J., ZHANG, X., & CHEN, W.-W. (2016) · Biomedical Reports · doi:10.3892/br.2016.630 · Cited by 1,023
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,004
A Familial Alzheimer's Disease Locus on Chromosome 1
Levy-Lahad, E., Wijsman, E. M., Nemens, E., Anderson, L., Goddard, K. A. B., Weber, J. L., Bird, T. D., & Schellenberg, G. D. (1995) · Science · doi:10.1126/science.7638621 · Cited by 813
Tau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806
Alzheimer's Disease: A Central Role for Amyloid
Selkoe, D. J. (1994) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199409000-00003 · Cited by 751
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
Turner, R. S., Thomas, R. G., Craft, S., van Dyck, C. H., Mintzer, J., Reynolds, B. A., Brewer, J. B., Rissman, R. A., Raman, R., Aisen, P. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002035 · Cited by 736
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Sanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., Devidze, N., Ho, K., Yu, G.-Q., Palop, J. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121081109 · Cited by 638
Targeting the β secretase BACE1 for Alzheimer's disease therapy
Yan, R., & Vassar, R. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 630
Structural characterization of the core of the paired helical filament of Alzheimer disease.
Wischik, C. M., Novak, M., Edwards, P. C., Klug, A., Tichelaar, W., & Crowther, R. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4884 · Cited by 595
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
Danysz, W., & Parsons, C. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02057.x · Cited by 500
Claxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan, A., Callaghan, M., Arbuckle, M., Behl, C., & Craft, S. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141791 · Cited by 467
Immune System Response in Alzheimer's Disease
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100029863 · Cited by 459
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
Zhang, Y., McLaughlin, R., Goodyer, C., & LeBlanc, A. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200110119 · Cited by 418
Marsh, S. E., Abud, E. M., Lakatos, A., Karimzadeh, A., Yeung, S. T., Davtyan, H., Fote, G. M., Lau, L., Weinger, J. G., Lane, T. E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525466113 · Cited by 411
De-Paula, V. J., Radanovic, M., Diniz, B. S., & Forlenza, O. V. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_14 · Cited by 405
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy
Khlistunova, I., Biernat, J., Wang, Y., Pickhardt, M., von Bergen, M., Gazova, Z., Mandelkow, E., & Mandelkow, E.-M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507753200 · Cited by 351
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., & Aisen, P. S. (2011) · Neurology · doi:10.1212/wnl.0b013e318228bf11 · Cited by 336
Hemming, M. L., & Selkoe, D. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508460200 · Cited by 332
Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J. K., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-11.2012 · Cited by 317
The Revitalized Tau Hypothesis on Alzheimer's Disease
Maccioni, R. B., Farías, G., Morales, I., & Navarrete, L. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.03.007 · Cited by 312
Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 309
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R. W., Younkin, S., Younkin, L., Schiff, R., & Weksler, M. E. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 301
Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment
Lombardo, S., & Maskos, U. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.018 · Cited by 299
Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70088-2 · Cited by 294
Tucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140741 · Cited by 272
Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269
Neurobiology of Alzheimer′s disease
Mohandas, E., Rajmohan, V, & Raghunath, B. (2009) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.44908 · Cited by 268
Danysz, W., Parsons, C. G., MÖbius, H.-J., StÖffler, A., & Quack, G. (2000) · Neurotoxicity Research · doi:10.1007/bf03033787 · Cited by 263
Amyloid–cholinesterase interactions: Implications for Alzheimer’s disease
Inestrosa, N. C., Dinamarca, M. C., & Alvarez, A. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.06238.x · Cited by 261
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
Butchart, J., Brook, L., Hopkins, V., Teeling, J., Püntener, U., Culliford, D., Sharples, R., Sharif, S., McFarlane, B., Raybould, R., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001617 · Cited by 248
The amyloid deposits in Alzheimer's disease: their nature and pathogenesis.
Glenner, G. G., Wong, C. W., Quaranta, V., & Eanes, E. D. (1984) · PubMed · Cited by 244
The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics
Carreiras, M., Mendes, E., Perry, M., Francisco, A., & Marco-Contelles, J. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990135 · Cited by 240
Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease
Li, F., Gong, Q., Dong, H., & Shi, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212798919075 · Cited by 230
Review article What causes alzheimer’s disease?
A. Armstrong, R. (2013) · Folia Neuropathologica · doi:10.5114/fn.2013.37702 · Cited by 217
Glutamate transmission and toxicity in alzheimer's disease
Greenamyre, J. T., Maragos, W. F., Albin, R. L., Penney, J. B., & Young, A. B. (1988) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(88)90102-9 · Cited by 197
Tau-Centric targets and drugs in clinical development for the treatment of alzheimer's disease
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Zecca, C., Barulli, M. R., Bellomo, A., Pilotto, A., et al. (2016) · BioMed Research International · doi:10.1155/2016/3245935 · Cited by 195
Raskin, J., Cummings, J., Hardy, J., Schuh, K., & Dean, R. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150701103107 · Cited by 188
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis
Cudkowicz, M., Bozik, M. E., Ingersoll, E. W., Miller, R., Mitsumoto, H., Shefner, J., Moore, D. H., Schoenfeld, D., Mather, J. L., Archibald, D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2579 · Cited by 178
Piette, F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., Marquis, C., Mely, J., Hugonot-Diener, L., Kinet, J.-P., et al. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt75 · Cited by 173
Phase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer's Disease
(2014) · New England Journal of Medicine · doi:10.1056/nejmc1402193 · Cited by 169
Furukawa‐Hibi, Y., Alkam, T., Nitta, A., Matsuyama, A., Mizoguchi, H., Suzuki, K., Moussaoui, S. M., Yu, Q.-S., Greig, N. H., Nagai, T., et al. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.07.035 · Cited by 164
The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Blasco, H., Mavel, S., Corcia, P., & Gordon, P. H. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140916120118 · Cited by 164
Wilkinson, D., Windfeld, K., & Colding-Jørgensen, E. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70198-x · Cited by 164
Gutzmann, H., & Hadler, D. (1998) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-7508-8_30 · Cited by 162
Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases
Sadek, B. S., Saad, A. K., Sadeq, A. S., Jalal, F. Y., & Stark, H. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.051 · Cited by 162
Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits
Tong, X.-K., Lecrux, C., & Hamel, E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0169-12.2012 · Cited by 160
Protein S -Nitrosylation as a Therapeutic Target for Neurodegenerative Diseases
Nakamura, T., & Lipton, S. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.002 · Cited by 160
Lahmy, V., Meunier, J., Malmström, S., Naert, G., Givalois, L., Kim, S. H., Villard, V., Vamvakides, A., & Maurice, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.70 · Cited by 159
Eriksdotter-Jönhagen, M., Linderoth, B., Lind, G., Aladellie, L., Almkvist, O., Andreasen, N., Blennow, K., Bogdanovic, N., Jelic, V., Kadir, A., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000336051 · Cited by 158
Weinreb, O., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2012) · Current Drug Targets · doi:10.2174/138945012799499794 · Cited by 154
Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001877 · Cited by 151
Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease
Nordberg, A. K. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213804.59187.2d · Cited by 151
Alzheimer disease: A tale of two prions
Nussbaum, J. M., Seward, M. E., & Bloom, G. S. (2013) · Prion · doi:10.4161/pri.22118 · Cited by 147
Lin, C., Chen, P.-K., Chang, Y., Chuo, L.-J., Chen, Y.-S., Tsai, G. E., & Lane, H. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.010 · Cited by 143
Lawson, D. H., Lee, S., Zhao, F., Tarhini, A. A., Margolin, K. A., Ernstoff, M. S., Atkins, M. B., Cohen, G. I., Whiteside, T. L., Butterfield, L. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0500 · Cited by 141
Valera, E., Spencer, B. J., & Masliah, E. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0397-z · Cited by 141
Baddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R., & Wischik, C. M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219352 · Cited by 134
Yang, G., Wang, Y., Sun, J., Zhang, K., & Liu, J. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150813143520 · Cited by 133
Development of AFFITOPE vaccines for Alzheimer's disease (AD) — From concept to clinical testing
Schneeberger, A., Mandler, M., Otava, O., Zauner, W., Mattner, F., & Schmidt, W. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0070-5 · Cited by 133
Amyloid Fibres: Inert End-Stage Aggregates or Key Players in Disease?
Tipping, K. W., van Oosten‐Hawle, P., Hewitt, E. W., & Radford, S. E. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.10.002 · Cited by 126
Sinha, S., Du, Z., Maiti, P., Klärner, F., Schrader, T. H., Wang, C., & Bitan, G. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200133x · Cited by 122
Li, X.-H., Li, X.-H., Zhang, Y.-Y., Wang, M., & Wang, D. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s40405 · Cited by 114
SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
Maher‐Edwards, G., Dixon, R., Hunter, J. A., Gold, M., Hopton, G., Jacobs, G., Hunter, J., & Williams, P. M. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2562 · Cited by 113
Neumann, U., Rueeger, H., Machauer, R., Veenstra, S. J., Lueoend, R. M., Tintelnot-Blomley, M., Laue, G., Beltz, K., Vogg, B., Schmid, P., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0033-8 · Cited by 113
Davtyan, H., Ghochikyan, A., Petrushina, I., Hovakimyan, A., Davtyan, A., Poghosyan, A., Marleau, A. M., Movsesyan, N., Kiyatkin, A., Rasool, S., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4672-12.2013 · Cited by 112
Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer’s Disease?
Qian, Z., & Ke, Y. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00216 · Cited by 106
Jouroukhin, Y., Ostritsky, R., Assaf, Y., Pelled, G., Giladi, E., & Gozes, I. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.012 · Cited by 105
Kume, K., Hanyu, H., Sakurai, H., Takada, Y., Onuma, T., & Iwamoto, T. (2011) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2011.00746.x · Cited by 104
Jacobsen, H., Ozmen, L., Caruso, A., Narquizian, R., Hilpert, H., Jacobsen, B., Terwel, D., Tanghe, A., & Bohrmann, B. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1405-14.2014 · Cited by 99
Maccecchini, M. L., Chang, M. Y., Pan, C., John, V., Zetterberg, H., & Greig, N. H. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302589 · Cited by 98
Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease
Wang, C. Y., Finstad, C. L., Walfield, A. M., Sia, C., Sokoll, K. K., Chang, T.-Y., Fang, X. D., Hung, C. H., Hutter-Paier, B., & Windisch, M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.031 · Cited by 98
Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status
Ramírez, M. J., Lai, M. K. P., Tordera, R. M., & Francis, P. T. (2014) · Drugs · doi:10.1007/s40265-014-0217-5 · Cited by 95
Leuner, K., Stockburger, C., Denzer, I., Eckert, G. P., & Müller, W. E. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394625-6.00007-6 · Cited by 94
Alam, J. J. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150277 · Cited by 92
Tamibarotene: A Candidate Retinoid Drug for Alzheimer’s Disease
Fukasawa, H., Nakagomi, M., Yamagata, N., Katsuki, H., Kawahara, K., Kitaoka, K., Miki, T., & Shudo, K. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00314 · Cited by 91
Hunsberger, H. C., Weitzner, D. S., Rudy, C. C., Hickman, J. E., Libell, E. M., Speer, R. R., Gerhardt, G. A., & Reed, M. N. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13230 · Cited by 91
Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics
Deardorff, W. J., & Grossberg, G. T. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1200972 · Cited by 91
Bomba, M., Ciavardelli, D., Silvestri, E., Canzoniero, L. M. T., Lattanzio, R., Chiappini, P. B. O., Piantelli, M., Ilio, C. D., Consoli, A., & Sensi, S. L. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.139 · Cited by 89
Landen, J. W., Zhao, Q., Cohen, S., BORRIE, M. J., Woodward, M., Billing, C. B., Bales, K. R., Alvey, C. W., McCush, F., Yang, J., et al. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31827db49b · Cited by 88
Hickman, D. T., López-Deber, M. P., Ndao, D. M., Silva, A. B., Nand, D., Pihlgren, M., Giriens, V., Madani, R., St-Pierre, A., Karastaneva, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186338 · Cited by 85
Cholinesterase Inhibition in Alzheimer's Disease: Is Specificity the Answer?
Macdonald, I. R., Rockwood, K. J., Martin, E. V., & Darvesh, S. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140219 · Cited by 84
Chartier‐Harlin, M., Crawford, F., Hamandi, K., Mullan, M., Goate, A., Hardy, J., Backhovens, H., Martin, J., & Broeckhoven, C. V. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90738-f · Cited by 82
Egefjord, L., Gejl, M., Møller, A., Brændgaard, H., Gottrup, H., Antropova, O., Møller, N., Poulsen, H. E., GJEDDE, A. H., Brock, B., et al. (2012) · PubMed · Cited by 80
Chiu, W., Depboylu, C., Hermanns, G., Maurer, L., Windolph, A., Oertel, W. H., Ries, V., & Höglinger, G. U. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.020 · Cited by 78
Function and Dysfunction of the Presenilins
Sisodia, S. S., Kim, S. H., & Thinakaran, G. (1999) · The American Journal of Human Genetics · doi:10.1086/302475 · Cited by 76
Barone, E., Mancuso, C., Di Domenico, F., Sultana, R., Murphy, M. P., Head, E., & Butterfield, D. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07538.x · Cited by 75
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy
Chumakov, I. M., Nabirotchkin, S., Cholet, N., Milet, A., Boucard, A., Toulorge, D., Pereira, Y., Graudens, E., Traoré, S., Foucquier, J., et al. (2015) · Scientific Reports · doi:10.1038/srep07608 · Cited by 70
Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease
Relkin, N. R. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0041-4 · Cited by 67
Frölich, L., on behalf of the Sirocco Investigators, Ashwood, T. J., Nilsson, J., & Eckerwall, G. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101554 · Cited by 63
Yao, J., Zhao, L., Mao, Z., Chen, S., Wong, K., To, J., & Brinton, R. D. (2013) · Brain Research · doi:10.1016/j.brainres.2013.02.021 · Cited by 63
Lues, I., Weber, F., Meyer, A., Uli, B., Hoffmann, T., Kühn‐Wache, K., Manhart, S., Heiser, U. F., Pokorny, R., Chiesa, J., et al. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.08.002 · Cited by 62
Shah, R. C., Matthews, D. C., Andrews, R. D., Capuano, A. W., Fleischman, D. A., VanderLugt, J. T., & Colca, J. R. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140616113406 · Cited by 58
Farias, G. A., Guzmán‐Martínez, L., Delgado, C., & Maccioni, R. B. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132741 · Cited by 55
Shindo, T., Takasaki, K., Uchida, K., Onimura, R., Kubota, K., Uchida, N., Irie, K., Katsurabayashi, S., Mishima, K., Nishimura, R., et al. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00387 · Cited by 54
Influence of isotretinoin on hippocampal-based learning in human subjects
Ormerod, A. D., Thind, C. K., Rice, S. A., Reid, I., Williams, J. H. G., & McCaffery, P. J. A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2611-y · Cited by 48
Bryostatin-1 Restores Hippocampal Synapses and Spatial Learning and Memory in Adult Fragile X Mice
Sun, M., Hongpaisan, J., Lim, C. S., & Alkon, D. L. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214098 · Cited by 46
Retinoids for treatment of Alzheimer’s disease
Lerner, A. J., Gustaw‐Rothenberg, K., Smyth, S., & Casadesus, G. (2012) · BioFactors · doi:10.1002/biof.196 · Cited by 44
Developing pharmacological therapies for Alzheimer disease
Iqbal, K., & Grundke, I. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7221-9 · Cited by 43
Bhattacharya, S., Maelicke, A., & Montag, D. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142421 · Cited by 41
Cognitive Effects of Statin Medications
Kelley, B. J., & Glasser, S. P. (2014) · CNS Drugs · doi:10.1007/s40263-014-0147-5 · Cited by 40
Sevigny, J., Chiao, P., Williams, L. J., Chen, T., Ling, Y., O'Gorman, J., Höck, C., Nitsch, R. M., & Sandrock, A. W. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.07.367 · Cited by 40
Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype
Lane, R. M., & He, Y. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.005 · Cited by 39
Mandavilli, A. (2006) · Nature Medicine · doi:10.1038/nm0706-747 · Cited by 37
Shin, J. H., Lee, Y. A., Lee, J. K., Lee, Y. B., Cho, W., Im, D. S., Lee, J. H., Yun, B. S., Springer, J. E., & Gwag, B. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07771.x · Cited by 36
Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer’s disease
Chalmers, K. A., Wilcock, G. K., Vinters, H. V., Perry, E. K., Perry, R., Ballard, C. G., & Love, S. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5000-2 · Cited by 36
Kurata, T., Miyazaki, K., Kozuki, M., Morimoto, N., Ohta, Y., Ikeda, Y., & Abe, K. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.030 · Cited by 34
Muggia, F. M., & Kudlowitz, D. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000053 · Cited by 34
Jelinek, G. A., Weiland, T. J., Hadgkiss, E. J., Marck, C. H., Pereira, N. G., & van der Meer, D. M. (2015) · Neurological Research · doi:10.1179/1743132815y.0000000036 · Cited by 33
Lack of support for bexarotene as a treatment for Alzheimer's disease
O‘Hare, E., Jeggo, R., Kim, E., Barbour, B., Walczak, J., Palmer, P., Lyons, T., Page, D., Hanna, D., Meara, J., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.020 · Cited by 33
Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes
Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 32
Anand, R., Seiberling, M., Kamtchoua, T., et al. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746040-00007 · Cited by 32
Weinreb, O., Badinter, F., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.009 · Cited by 31
Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system
Pradal, J., Zuluaga, M.-F., Maudens, P., Waldburger, J., Seemayer, C. A., Doelker, É., Gabay, C., Jordan, O., & Allémann, É. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.017 · Cited by 27
Hu, C., Adedokun, O. J., Ito, K., Raje, S. V., & Lu, M. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.393 · Cited by 26
Alexander, R., Budd, S. L., Russell, M., Kugler, A. R., Cebers, G., Ye, N. Z., Olsson, T., Burdette, D., Maltby, J., Paraskos, J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.033 · Cited by 24
Shaddinger, B. C., Xu, Y., Roger, J., Macphee, C. H., Handel, M. L., Baidoo, C. A., Magee, M. H., Lepore, J. J., & Sprecher, D. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083094 · Cited by 22
Lee, D. S., Choi, J., Kim, S., & Kim, S. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00906 · Cited by 22
Sugiyama, A., Saitoh, A., Inagaki, M., Oka, J., & Yamada, M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.06.007 · Cited by 21
Statins for Treating Alzheimer's Disease: Truly Ineffective?
Liang, T. B., Li, R., & Cheng, O. (2015) · European Neurology · doi:10.1159/000382128 · Cited by 21
Lachno, D. R., Evert, B. A., Vanderstichele, H., Robertson, M., Demattos, R. B., Konrad, R. J., Talbot, J. A., Racke, M. M., & Dean, R. A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122317 · Cited by 21
Takamura, Y., Ono, K., Matsumoto, J., Yamada, M., & Nishijo, H. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.037 · Cited by 21
Pradier, L., Cohen, C., Blanchard, V., Debeir, T., Barnéoud, P., Canton, T., Ménager, J., Bohme, A., Rooney, T., Guillet, M., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1678 · Cited by 19
The Potential of Proteomics in Understanding Neurodegeneration
Pal, R., Larsen, J. P., & Møller, S. G. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.05.002 · Cited by 19
Kukharsky, M. S., Овчинников, Р. К., & Бачурин, С. О. (2015) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20151156103-114 · Cited by 18
Alzheimer's disease clinical trials: past failures and future opportunities
Yaari, R., & Hake, A. M. (2015) · Clinical Investigation · doi:10.4155/cli.14.127 · Cited by 16
Molecular genetics of Alzheimer’s disease
Sorbi, S., Nacmias, B., & Forleo, P. (1993) · Aging Clinical and Experimental Research · doi:10.1007/bf03324196 · Cited by 16
Thomsen, M. S., Andreasen, J. T., Arvaniti, M., et al. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160127112357 · Cited by 16
Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose
Sun, X., Zhao, L., Zhao, N., Pan, X.-L., Fei, G.-Q., Jin, L., & Zhong, C. (2012) · Neuroscience Bulletin · doi:10.1007/s12264-012-1264-0 · Cited by 15
Novák, M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.246 · Cited by 14
Pivotal trials for β-secretase inhibitors in Alzheimer's
Sheridan, C. (2015) · Nature Biotechnology · doi:10.1038/nbt0215-115 · Cited by 13
Advances in Psychopharmacology for Anxiety Disorders
Garakani, A., Murrough, J. W., & Iosifescu, D. V. (2014) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.12.2.152 · Cited by 13
The effectiveness of amiridin in senile dementia of the Alzheimer's type
Bukatina, E. E., Григорьева, Ю. В., & Sokol'chik, E. I. (1993) · Neuroscience and Behavioral Physiology · doi:10.1007/bf01182643 · Cited by 11
Othman, A. A., Meier, A., Ritchie, C. W., Florian, H., Gault, L. M., & Tang, Q. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.081 · Cited by 11
Alzheimer’s Disease: Theories of Causation
Bradley, W. G. (1990) · Advances in experimental medicine and biology · doi:10.1007/978-1-4613-0665-8_3 · Cited by 8
Arrested cell proliferation through cysteine protease activity of eukaryotic ribosomal protein S4
Madasu, Y., Sudhamalla, B., Rao, P. N., Roy, K. R., Ramakrishna, D., Syed, G. H., Ramaiah, K. V. A., & Bhuyan, A. K. (2012) · The FASEB Journal · doi:10.1096/fj.12-217752 · Cited by 5
Cited by
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Economic burden of Alzheimer disease and managed care considerations
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88482 · Cited by 398
Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy
Zhou, Y., Zhu, F., Liu, Y., Zheng, M., Wang, Y., Zhang, D., Anraku, Y., Zou, Y., Li, J., Wu, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc7031 · Cited by 300
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
Metadata
- Authors
- Bachurin, S. O., Bovina, E. V., & Ustyugov, A. A.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2017-01-13
- Volume
- 37
- Issue
- 5
- Pages
- 1186-1225
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2572208524
- Cited by
- 304
- References
- 152
- FWCI
- 26.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.